Product Growth Genovis continues to expand its enzyme portfolio with new generations and specialized proteases such as FabRICATOR second generation, IgM-specific protease, IgASAP, ImpaRATOR, IgMBRAZOR, and PNGase F Automation, presenting sales opportunities for lab automation and analytical workflows in biopharma R&D and manufacturing.

Target Markets With a focus on biopharmaceutical development and production of monoclonal antibodies, ADCs, biosimilars and bispecifics, Genovis enzymes align with customers pursuing glycosylation analysis, IgG digestion, de-glycosylation and conjugation, offering cross-selling potential across discovery, QC, and manufacturing teams.

Global Reach Global availability of SmartEnzymes suggests potential for multinational biopharma accounts and CRO/CMO partnerships; emphasize regional support, automation compatibility, and scalable solutions to win larger enterprise deals.

Automation Fit Recent PNGase F Automation and enzyme formats designed for development and QC workflows indicate strong resonance with labs seeking integrated, automation-friendly tools, creating upsell opportunities for instrument vendors and workflow consultants.

Strategic Partnerships Active advisory and partnership moves (e.g., with Carnegie Investment Bank) reflect a growth-ready company; leverage this momentum to position Genovis as a strategic enzyme partner in biotech funding rounds, partnerships with analytical service providers, and co-development opportunities.